Clinical trials: Liver Tumour
Hepatocellular Carcinoma
SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of SBRT for perivascular hepatocellular carcinoma, compared with RFA.
- Trial name
- SAIL (NCT04434989)
- Testing
- Stereotactic Body Radiation Therapy, radiofrequency ablation
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
SBRT With DIBH for HCC After TACE and Lipiodol Marking
Stereotactic Body Radiation Therapy (SBRT) for hepatocellular carcinoma (HCC) with radical dose achieved similar results with radiofrequency ablation (RF) and radical surgery, according to previous studies.
- Trial name
- NCT05021250
- Testing
- Lipiodol marking
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Liver Cancer
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
- Trial name
- NCT00374660
- Testing
- Oxaliplatin, Irofulven
- Where
- 7 sites in France
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Liver Cancer, Hepatocellular Carcinoma
Application of 3D Printing in Laparoscopic Surgery of Liver Tumors
To explore the utility of personalized 3D printed liver models in planning and navigating laparoscopic resections.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- NCT03744624
- Testing
- Laparoscopic liver resection, 3D printing model
- Where
- Poland
- Volunteers
- 85 people
- Sponsor
- Jagiellonian University
Liver Diseases
Early Detection of Hepatocellular Carcinoma in a High-risk Prospective Cohort (ELEGANCE)
Hepatocellular carcinoma (HCC) is the 7th most common cause of cancer death globally but only 20% are diagnosed in its early stages where cure is possible.
- Trial name
- NCT04965259
- Where
- 14 sites in Singapore
- Volunteers
- 2,002 people
- Sponsor
- National Cancer Centre, Singapore
NAFLD, Diabetes
DIAbetes and NAFLD
Non-alcoholic hepatic steatosis (NAFLD) is characterised by the excessive accumulation of triglycerides in the liver and is often associated, in the absence of significant alcohol consumption, with insulin resistance and…
- Conditions
- NAFLD, Diabetes, NASH, Fibrosis, Liver
- Trial name
- DIANA (NCT06315361)
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Hepatocellular Carcinoma
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy.
- Trial name
- HCC (NCT04560894)
- Testing
- SCT-I10A, SCT510, Sorafenib 200mg
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Sinocelltech Ltd.
Carcinoma, Hepatocellular
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer worldwide, characterized by complex and variable disease progression and significant treatment challenges.
- Trial name
- NCT07160361
- Testing
- Lenvatinib + losartan
- Volunteers
- 56 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepatocellular Carcinoma
Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard…
- Trial name
- NCT05072041
- Testing
- Nexsphere™
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Next Biomedical Co., Ltd.
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma
Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy
Radiation therapy is a highly effective modality for managing localized solid tumors and has become a fundamental component of treating unresectable hepatocellular carcinoma.
- Trial name
- NCT06379256
- Testing
- Photon or proton radiotherapy
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Cancer, Physical Activity
Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors
The purpose of this study is to conduct a 6-month pilot randomized trial to determine the feasibility and acceptability of theory-based mobile weight loss interventions for survivors of adolescent and young adult cancer (AYAs).
- Conditions
- Cancer, Physical Activity, Cancer Survivorship, Mental Health
- Trial name
- AYAConnect (NCT06171945)
- Testing
- AYA Connect intervention, Positive Psychology (PP) intervention, Positive Psychology Plus (PP+) intervention
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Liver Cancer
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy
- Trial name
- NCT07053072
- Testing
- Low Dose PD-1 mRNA LNP Vaccine, High dose PD-1 mRNA LNP vaccines
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma
VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway
The investigators study the VEGF signaling in HCC cell lines and its mechanism in HCC growth, proliferation and apoptosis.
- Trial name
- HCC (NCT01892072)
- Testing
- surgical treatment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Hepatocellular, Liver Dysfunction
Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with…
- Trial name
- LiFE (NCT01490203)
- Testing
- Gd-EOB-DTPA, MRI
- Where
- 4 sites in South Korea
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Hepatocellular Carcinoma Resectable
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of surgical treatments for hepatocellular carcinoma (HCC), including preoperative…
- Trial name
- NCT06003673
- Testing
- neoadjuvant therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Hepatocellular Carcinoma
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
- Trial name
- NCT07813572
- Testing
- ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hepatocellular Carcinoma
TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
The purpose of this study is to evaluate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) plus Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in advanced hepatocellular carcinoma (BCLC-C Stage)…
- Trial name
- NCT05882370
- Testing
- Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fei Gao
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.